These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 22338543)

  • 41. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy].
    Brunner J; Seybold U; Gunsenheimer-Bartmeyer B; Hamouda O; Bogner JR;
    Dtsch Med Wochenschr; 2010 Jun; 135(23):1166-70. PubMed ID: 20514595
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Positioning of HIV-protease inhibitors in clinical practice.
    Andreoni M; Perno CF
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):10-8. PubMed ID: 22338543
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 46. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.
    Fischl MA
    AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The picture of future therapy.
    Gazzard B
    Int J Clin Pract Suppl; 1999 Jun; 103():45-8. PubMed ID: 10622045
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.